Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | UGCG | Q16739 | 4/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.31 |
| ▸ | GBA1 | P04062 | 3/20 | 0.31 |
| ▸ | LCT | P09848 | 3/20 | 0.31 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | SI | P14410 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611164 | 0.76 | KCNH2 (0.42) | — | |
| SCHEMBL21167279 | 0.70 | DRD2 (0.44) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11235787 | 0.70 | MAOB (0.34) | LMNA | |
| SCHEMBL4613107 | 0.70 | L3MBTL1 (0.33) | LMNA | |
| SCHEMBL11241311 | 0.69 | L3MBTL1 (0.32) | LMNA | |
| SCHEMBL2084122 | 0.69 | CNR1 (0.40) | — | |
| SCHEMBL8066377 | 0.69 | HRH1 (0.43) | OPRL1SMN1; SMN2 | |
| SCHEMBL17818423 | 0.69 | L3MBTL1 (0.35) | OPRM1LMNA | |
| SCHEMBL13067453 | 0.69 | L3MBTL1 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL23964575 | 0.68 | L3MBTL1 (0.35) | ALDH1A1LMNASMN1; SMN2ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294671-B1 | UTILISATION OF KETONES AS PRECURSORS OF ACTIVE COMPOUNDS | FIRMENICH & CIE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-6949680-B2 | Ketones as precursors of active compounds | FIRMENICH SA (CH) | 2005-09-27 | — | — | US | disclosed |
| US-20030129212-A1 | Ketones as precursors of active compounds | FIRMENICH SA (CH) | 2003-07-10 | — | — | US | disclosed |
| EP-1294671-A2 | UTILISATION OF KETONES AS PRECURSORS OF ACTIVE COMPOUNDS | FIRMENICH SA (CH) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096272-A2 | UTILISATION OF KETONES AS PRECURSORS OF ACTIVE COMPOUNDS | FIRMENICH SA (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129212-A1 | Ketones as precursors of active compounds | PKN3, PKM, FPR3 | OPRM1 277/4885OPRD1 241/4885OPRK1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.